526 related articles for article (PubMed ID: 6402387)
21. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
[TBL] [Abstract][Full Text] [Related]
22. Emergency contraception: a review.
Haspels AA
Contraception; 1994 Aug; 50(2):101-8. PubMed ID: 7956209
[TBL] [Abstract][Full Text] [Related]
23. The morning after: novel hormonal approaches to postcoital interception.
Adashi EY
Fertil Steril; 1983 Mar; 39(3):267-9. PubMed ID: 6402385
[TBL] [Abstract][Full Text] [Related]
24. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
Lemay A; Dewailly SD; Grenier R; Huard J
J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
[TBL] [Abstract][Full Text] [Related]
25. A possible mechanism of action of danazol and an ethinylestradiol/norgestrel combination used as postcoital contraceptive agents.
Rowlands S; Kubba AA; Guillebaud J; Bounds W
Contraception; 1986 Jun; 33(6):539-45. PubMed ID: 3533419
[TBL] [Abstract][Full Text] [Related]
26. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
[TBL] [Abstract][Full Text] [Related]
27. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
[TBL] [Abstract][Full Text] [Related]
28. Ethinylestradiol from contraceptive formulations and the ovarian response: an estrogen dose-dependency on natural estradiol concentrations.
Sojo-Aranda I; Cortés-Gallegos V
Gynecol Endocrinol; 1995 Mar; 9(1):63-6. PubMed ID: 7793302
[TBL] [Abstract][Full Text] [Related]
29. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
30. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of two contraceptive vaginal rings releasing norethindrone acetate and differing doses of ethinyl estradiol.
Weisberg E; Fraser IS; Mishell DR; Lacarra M; Darney P; Jackanicz TM
Contraception; 1999 May; 59(5):305-10. PubMed ID: 10494484
[TBL] [Abstract][Full Text] [Related]
32. Ovarian activity suppression by two different low-dose triphasic oral contraceptives.
van der Does J; Exalto N; Dieben T; Bennink HC
Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599
[TBL] [Abstract][Full Text] [Related]
33. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
34. Interfering with implantation by postcoital estrogen administration. II. Endometrium epithelial cell ultrastructure.
van Santen MR; Haspels AA; Heijnen HF; Rademakers LH
Contraception; 1988 Dec; 38(6):711-24. PubMed ID: 3219856
[TBL] [Abstract][Full Text] [Related]
35. The effect of ethinyl estradiol 20 mcg and levonorgestrel 250 mcg on the pituitary-ovarian function during normal tablet-taking and when tablets are missed.
Nuttall ID; Elstein M; McCafferty E; Seth J; Cameron ED
Contraception; 1982 Aug; 26(2):121-35. PubMed ID: 6814817
[TBL] [Abstract][Full Text] [Related]
36. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
[TBL] [Abstract][Full Text] [Related]
37. [Post-coital contraception].
Serfaty D
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):359-64. PubMed ID: 12280207
[TBL] [Abstract][Full Text] [Related]
38. [Plasma concentrations of LH and of sex steroids during the normal menstrual cycle and during contraceptive treatment].
Bayard F; Louvet JP; Moatti JP; Smilovici W; Duguet L; Boulard C
J Gynecol Obstet Biol Reprod (Paris); 1975; 4(7):915-26. PubMed ID: 767402
[TBL] [Abstract][Full Text] [Related]
39. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
Shumin X; Johannisson E; Landgren BM; Diczfalusy E
Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
[TBL] [Abstract][Full Text] [Related]
40. Further studies on pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1981 Aug; 24(2):159-72. PubMed ID: 6794980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
